Compare BLIN & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLIN | MBAI |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 10.6M |
| IPO Year | 2018 | N/A |
| Metric | BLIN | MBAI |
|---|---|---|
| Price | $0.97 | $1.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.62 | N/A |
| AVG Volume (30 Days) | ★ 60.4K | 51.2K |
| Earning Date | 06-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,568,000.00 | N/A |
| Revenue This Year | $22.67 | N/A |
| Revenue Next Year | $21.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $1.31 |
| 52 Week High | $2.22 | $3.92 |
| Indicator | BLIN | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 62.37 | 48.03 |
| Support Level | $0.92 | $1.38 |
| Resistance Level | $1.06 | $1.87 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 77.82 | 45.28 |
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.